Skin and plasma autofluorescence during hemodialysis: A pilot study

Artificial Organs

Volumn 38, Issue 6, 2014, Pages 515-518

  Graaff, Reindert ^a   Arsov, Stefan ^b   Ramsauer, Bernd ^d   Koetsier, Marten ^b   Sundvall, Nils ^d   Engels, Gerwin E ^c   Sikole, Aleksandar ^b   Lundberg, Lennart ^d   Rakhorst, Gerhard ^b   Stegmayr, Bernd ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Universities of Groningen   (Netherlands)

^c Haemoscan   (Netherlands)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Advanced glycation end products; Hemodialysis; Plasma autofluorescence; Skin autofluorescence

Indexed keywords

GLYCOSYLATION; HEMODIALYZERS; PATIENT TREATMENT;

ADVANCED GLYCATION END PRODUCTS; AUTOFLUORESCENCE; HAEMODIALYSIS; HEALTHY PERSONS; HEMODIALYSIS PATIENT; MEASUREMENTS OF; PILOT STUDIES; PLASMA AUTOFLUORESCENCE; PROGNOSTIC MARKERS; SKIN AUTOFLUORESCENCE;

DIALYSIS;

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXCITATION; FEMALE; GLOMERULOPATHY; HEMODIALYSIS; HUMAN; HYPERTENSION; MALE; PILOT STUDY; PLASMA AUTOFLUORESCENCE; PRIORITY JOURNAL; RENOVASCULAR DISEASE; SKIN AUTOFLUOROSCENCE; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SKIN; SPECTROFLUOROMETRY; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS; SKIN; SPECTROMETRY, FLUORESCENCE; TIME FACTORS;

EID: 84901920865     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12205     Document Type: Article

References (19)

1. Meerwaldt R, Hartog JW, Graaff R, etal. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
2. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
3. Hartog JW, de Vries AP, Bakker SJ, etal. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006;21:2263-2269.
4. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-1152.
5. Smit AJ, Hartog JW, Voors AA, van Veldhuisen DJ. Advanced glycation endproducts in chronic heart failure. Ann N Y Acad Sci 2008;1126:225-230.
6. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986;314:403-408.
7. Mulder DJ, Water TV, Lutgers HL, etal. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523-535.
8. Meerwaldt R, Graaff R, Oomen P, etal. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
9. Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:527-533.
10. Miyata T, Hori O, Zhang J, etal. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996;98:1088-1094.
11. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002;17:871-878.
12. Vanholder R, Argiles A, Baurmeister U, etal. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
13. Vanholder R, De Smet R, Glorieux G, etal. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
14. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-310.
15. Busch M, Franke S, Muller A, etal. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004;66:338-347.
16. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010;12:399-403.
17. Koetsier M, Nur E, Chunmao H, etal. Skin color independent assessment of aging using skin autofluorescence. Opt Express 2010;18:14416-14429.
18. Miyata T, Ueda Y, Yoshida A, etal. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887.
19. Arsov S, Trajceska L, Van Oeveren W, etal. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 2013;37:E114-122.